Your Partner for
With the development of novel PET tracers for molecular imaging, Life Molecular Imaging (LMI) is focusing on a key area of modern medicine. LMI strives to be a leader in the field of molecular imaging by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.
We Provide Innovative PET Tracers
to Reduce the Burden of the Diseases
Our mission is to develop novel PET Tracers in the area of Molecular Imaging that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.
Life Molecular Imaging (LMI) was founded in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG by Piramal and is now part of Life Healthcare’s Alliance Medical.
LMI offers an integrated business including research and development laboratories. We have partnered with radiopharmacies, imaging centres and universities around the world to provide global access to our products. LMI develops and commercialises radiopharmaceuticals used in molecular imaging and has a promising pipeline of products in development in neurogenerative and cardiovascular diseases. Our flagship product Neuraceq® is used to detect the accumulation of amyloid proteins in the brain, which is considered a major cause of Alzheimer’s disease. Neuraceq® is nowadays approved and produced in many countries around the globe.
Our purpose is to provide innovative molecular imaging solutions to reduce the burden of disease. This will make life better for patients. As we expand and grow our business into new markets, our goal will positively impact a greater number of people in more regions. Playing a role in improving patients’ lives is important and aligns with our purpose. It’s about making life better for everyone.
Bayer spins out separate entity – Piramal Enterpises Ltd. becomes new owner
Neuraceq® approved by US & EU regulators
Acquired by Life Healthcare’s Alliance Medical
Bayer spins out separate entity - Piramal Enterpises Ltd. becomes new owner
Neuraceq® approved by US & EU regulators.
Aquired by Life's Alliance Medical
Part of the Life Healthcare International Group
An integrated business including research and development laboratories,
a network of cyclotrons, radiopharmacies and imaging facilities.
LMI develops and commercialises radiopharmaceuticals used in molecular imaging and has a promising pipeline of products in development across the neurogenerative and cardiovascular areas.
We are serving our customers with the help of the most experienced partners in the area of Molecular Imaging.
Our Leadership Team
The members of Life Molecular Imaging’s leadership team have been working for 20+ years in the pharmaceutical industry.
Ludger Dinkelborg, PhDManaging Director
Before joining Life Molecular Imaging, Dr. Dinkelborg served as Managing Director of Piramal Imaging GmbH, as Director of the Board of Piramal Imaging SA and was the Head of Diagnostic Imaging Research at Bayer HealthCare. He brings more than 30 years of R&D experience in the pharmaceutical industry.
He received his PhD in biology at Heinrich-Heine-University, Düsseldorf, Germany and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad-Adenauer-Foundation, attended the Cranfield Schering University course for managers, and the Stanford Executive Program, at Stanford School of Business, Stanford, CA.
Andrew Stephens, MD, PhDChief Medical Officer
Dr. Stephens has more than 30 years of experience in the pharmaceutical industry, primarily in the areas of neurodegenerative diseases, oncology and diagnostic imaging. Previously, he was Chief Medical Officer at Piramal Imaging and the VP Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. He has held positions of increasing responsibility at NeXagen/NeXstar, Gilead, Schering AG, and OSI Pharmaceuticals.
He received his BA cum laude in chemistry from the University of Colorado, Boulder. He also received an MD with honors and a PhD in biochemistry, biophysics and genetics from the University of Colorado, Boulder. Dr. Stephens is Board certified in Internal Medicine and had a clinical practice before entering pharmaceutical development.
Nico BeukmanChief Commercial Officer Europe, Middle East & Africa
Mr. Beukman has more than 25 years of experience in the medical industry with a proven track record for managing strategic growth and execution of sales, marketing and commercial activities. Throughout his career, he has implemented creative and effective solutions for driving revenue growth and improving profitability while managing multinational teams.
Prior to Life Molecular Imaging and Piramal Imaging, Mr. Beukman spent twelve years at Covidien now Curium, serving the company in various leadership roles. Mr. Beukman earned his National Diploma in Clinical Engineering at Tswane University of Technology in South Africa and more recently completed the Oxford Executive Leadership Program
Colleen Ruby, CNMT, RT(N)Chief Operating Officer, Americas and APAC
Ms. Ruby joined the organization in 2014 as Piramal Imaging’s Head of National Sales in the US to identify the market, establish the company’s brand, and to build a salesforce for the launch of Neuraceq® (florbetaben F-18). Ms. Ruby is a Certified and Registered Nuclear Medicine Technologist with more than thirty years of healthcare experience. She holds a degree in Science in Nuclear Medicine Technology and continuously updates her skill set via continuing education courses in health and business applications. Prior to joining the company, Ms. Ruby served as IBA Molecular’s Vice President of Sales and Marketing where she cultivated a professional organization of high-level Sales and Marketing specialists in the Nuclear and Molecular disciplines of the healthcare industry. Ms. Ruby was also previously employed by The University of Pittsburgh Medical Center. She is an active member of the Society of Nuclear Medicine and Molecular Imaging and participates on behalf of the company in the Medical Imaging and Technology Alliance.
Mathias Berndt, PhDHead Chemical R&D & Manufacturing
At Life Molecular Imaging, Mathias is responsible for our global commercial manufacturing network as well as the technical development of our pipeline assets.
Mathias has more than 15 years year experience in the pharmaceutical industry and radiopharmaceutical development at all stages from discovery to development to New Drug Application and commercialization. Prior to his current role at Life Molecular Imaging, he was Head of Chemical R&D at Piramal Imaging and held R&D positions at Bayer Healthcare and Schering AG.
Mathias studied chemistry at the Technical University Dresden, received his PhD in organic chemistry from the Free University Berlin and worked as a researcher at the Research Center Rossendorf.
Nick KarabatsosChief Commercial Officer, Americas and APAC
Nick Karabatsos leads the US commercial organization for Life Molecular Imaging Ltd. In this role, Nick is responsible for all sales and marketing activities in the North America and supporting our Asia Pacific markets.
Nick has more than 20 years of experience in the healthcare industry. He has a proven track record of strong strategic growth, leading and building diverse teams, and commercial success.
Prior to joining Life Molecular Imaging, Nick spent 21 years at GE Healthcare serving the company in various leadership roles. Most recently, Nick was the Vice President and General Manager of the Molecular Imaging (MI) business for the US and Canada. He was responsible for all activities associated with the MI business and lead the team to double digit growth and market share. Nick has his BS degree from the United States Military Academy at West Point and served 5 years in the US Army.
Adrian KarasiewiczHead of Finance
Adrian Karasiewicz is the Head of Finance at Life Molecular Imaging since May 2021, before served as Financial Controller since he joined the company in 2019. He brings more than 10 years of experience in corporate finance, serving before as an Accountant at Miranda Textiles and Financial Controller at Diehl Group.
He received his Master Degree in Finance and Accounting at Poznań University of Economics, Poland. He continues his development program at Association of Chartered Certified Accountants.
Tatjana IvermeeHead of HR
Tatjana Ivermee is the Head of HR at Life Molecular Imaging and has more than 20 years of international HR and recruitment experience.
For a number of years, she has also worked as a manager in Observational Research as part of a Clinical Research Organisation in order to understand a business from the inside and to see what challenges employees and managers have within an international dynamic client-oriented matrix environment. This helped her to optimise her support for the business when she returned to HR.
Tatjana is a committed people manager, who believes that working with people is not a job – it’s a passion.
Michel JongensChief Financial Officer - Molecular Imaging
Michel Jongens finished his bachelor’s in economics and joined the Dutch Wegener group in 1989 as finance manager. In 1994 he joined InteliCoat Technologies as finance director and he helped build this to be the European head office for this US subsidiary. In 2009 he joined Alliance Medical NE where he restructured the business and took on the role as MD in 2013, before coming CFO of AM NE and LMI in July 2018.
Donna FelkerHead of Legal
Ms. Felker has been practicing law in the United States for 18 years, primarily in the life sciences and outsourced services industries. Prior to becoming a lawyer, Ms. Felker spent 14 years in positions of increasing responsibility in domestic (US) and global operations and client management.
Ms. Felker completed her Bachelor Degrees in Business Administration (Financial Management) and Human Resources at the University of Delaware, her Master of Science Degree in Business Administration at Boston University, and her Juris Doctorate at Creighton University School of Law.
Compliance & Code of Conduct
As member of EFPIA (European Federation of Pharmaceutical Industries Association) Life Molecular Imaging is committed to comply with the EFPIA codes of standard as well as with applicable national laws and regulations for an open and transparent relationship with stakeholders across healthcare including healthcare professionals (HCPs), EU institutions and patient organizations.